US EditionPublished • loading... • Updated
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
- Sacituzumab Tirumotecan showed statistically significant improvement in progression-free survival compared to chemotherapy in advanced HR+/HER2- breast cancer, as concluded from the Phase 3 clinical study OptiTROP-Breast02.
- The study found that the PFS benefit was evident in all predefined subgroups, independent of HER2 status.
- The Center for Drug Evaluation accepted new indication applications for sac-TMT, allowing priority review for treatment in specific breast cancer patients who previously received other therapies.
- The findings suggest that sac-TMT is a safe and effective treatment option for patients previously treated for HR+/HER2- breast cancer.
Insights by Ground AI
42 Articles
42 Articles
The Berkshire Eagle+41 Reposted by 41 other sources
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's…
Coverage Details
Total News Sources42
Leaning Left4Leaning Right7Center12Last UpdatedBias Distribution52% Center
Bias Distribution
- 52% of the sources are Center
52% Center
L 17%
C 52%
R 31%
Factuality
To view factuality data please Upgrade to Premium
